BNP/CALL/ASTRAZENECA/14000/0.1/19.12.25 | Market Closed - Börse Stuttgart 01:52:42 17/05/2024 pm IST | ||
| 1.19 EUR | 0.00% |
|
| Current month | +2.59% | ||
| 1 month | +72.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.19 | 0.00% |
| 16/24/16 | 1.19 | -4.80% |
| 15/24/15 | 1.25 | -4.58% |
| 14/24/14 | 1.31 | -0.76% |
| 13/24/13 | 1.32 | -2.22% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 01:52 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC8HB7 |
| ISIN | DE000PC8HB76 |
| Date issued | 17/04/2024 |
| Strike | 14,000 p |
| Maturity | 19/12/2025 (581 Days) |
| Parity | 10 : 1 |
| Emission price | 0.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.35 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.02 € |
| Spread % | 1.67% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Warrants
- Warrant
